, Volume 213, Issue 2–3, pp 213–242 | Cite as

Presynaptic control of serotonin on striatal dopamine function

  • Sylvia Navailles
  • Philippe De DeurwaerdèreEmail author



The influences of the serotonergic system on dopamine (DA) neuron activity have received considerable attention during the last three decades due to the real opportunity to improve disorders related to central DA neuron dysfunctions such as Parkinson’s disease, schizophrenia, or drug abuse with serotonergic drugs. Numerous biochemical and behavioral data indicate that serotonin (5-HT) affects dopaminergic terminal function in the striatum.


The authors propose a thorough examination of data showing controversial effects induced by striatal 5-HT on dopaminergic activity.


Inhibitory and excitatory effects of exogenous 5-HT have been reported on DA release and synthesis, involving various striatal 5-HT receptors. 5-HT also promotes an efflux of DA through reversal of the direction of DA transport. By analogy with the mechanism of action described for amphetamine, the consequences of 5-HT entering DA terminals might explain both the excitatory and inhibitory effects of 5-HT on presynaptic DA terminal activity, but the physiological relevance of this mechanism is far from clear. The recent data suggest that the endogenous 5-HT system affects striatal DA release in a state-dependent manner associated with the conditional involvement of various 5-HT receptors such as 5-HT2A, 5-HT2C, 5-HT3, and 5-HT4 receptors.


Methodological and pharmacological issues have prevented a comprehensive overview of the influence of 5-HT on striatal DA activity. The distribution of striatal 5-HT receptors and their restricted influence on DA neuron activity suggest that the endogenous 5-HT system exerts multiple and subtle influences on DA-mediated behaviors.


DA release Endogenous serotonin Exogenous serotonin Carrier-mediated release 5-HT receptors DA transporter SSRI Citalopram Fluoxetine Haloperidol 5,7-DHT Freely moving rats Halothane-anesthetized rats 



This work was supported by grants from “Centre National de la Recherche Scientifique” and Bordeaux 2 University. The authors report no biomedical financial interest or potential conflicts of interest. The authors thank Dr. Martin Guthrie for linguistic assistance.


  1. Abramowski D, Rigo M, Duc D, Hoyer D, Staufenbiel M (1995) Localization of the 5-hydroxytryptamine2C receptor protein in human and rat brain using specific antisera. Neuropharmacology 34:1635–1645PubMedGoogle Scholar
  2. Adam Y, Edwards RH, Schuldiner S (2008) Expression and function of the rat vesicular monoamine transporter 2. Am J Physiol Cell Physiol 294:C1004–C1008PubMedGoogle Scholar
  3. Alex KD, Pehek EA (2007) Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission. Pharmacol Ther 113:296–320PubMedGoogle Scholar
  4. Alex KD, Yavanian GJ, McFarlane HG, Pluto CP, Pehek EA (2005) Modulation of dopamine release by striatal 5-HT2C receptors. Synapse 55:242–251PubMedGoogle Scholar
  5. Andersson JL, Nomikos GG, Marcus M, Hertel P, Mathé JM, Svensson TH (1995) Ritanserin potentiates the stimulatory effects of raclopride on neuronal activity and dopamine release selectively in the mesolimbic dopaminergic system. Naunyn-Schmiedeberg’s Arch Pharmacol 352:374–385Google Scholar
  6. Andrews CM, Lucki I (2001) Effects of cocaine on extracellular dopamine and serotonin levels in the nucleus accumbens. Psychopharmacology (Berl) 155:221–229Google Scholar
  7. Andrews DW, Patrick RL, Barchas J (1978) The effects of 5-hydroxytryptophan and 5-hydroxytryptamine on dopamine synthesis and release in rat brain striatal synaptosomes. J Neurochem 30:465–470PubMedGoogle Scholar
  8. Antonelli T, Fuxe K, Tomasini MC, Bartoszyk GD, Seyfried CA, Tanganelli S, Ferraro L (2005) Effects of sarizotan on the corticostriatal glutamate pathways. Synapse 58:193–199PubMedGoogle Scholar
  9. Awazi N, Guldberg HC (1978) On the interaction of 5-hydroxytryptophan and 5-hydroxytryptamine with dopamine metabolism in the rat striatum. Naunyn-Schmiedeberg’s Arch Pharmacol 303:63–72Google Scholar
  10. Azmitia EC, Segal M (1978) An autoradiographic analysis of the differential ascending projections of the dorsal and median raphe nuclei in the rat. J Comp Neurol 179:641–668PubMedGoogle Scholar
  11. Bachy A, Héaulme M, Giudice A, Michaud JC, Lefevre IA, Souilhac J, Manara L, Emerit MB, Gozlan H, Hamon M (1993) SR 57227A: a potent and selective agonist at central and peripheral 5-HT3 receptors in vitro and in vivo. Eur J Pharmacol 237:299–309PubMedGoogle Scholar
  12. Balcioglu A, Wurtman RJ (1998) Dexfenfluramine enhances striatal dopamine release in conscious rats via a serotoninergic mechanism. J Pharmacol Exp Ther 284:991–997PubMedGoogle Scholar
  13. Barnes JM, Barnes NM, Costall B, Ironside JW, Naylor RJ (1989) Identification and characterisation of 5-hydroxytryptamine 3 recognition sites in human brain tissue. J Neurochem 53:1787–1793PubMedGoogle Scholar
  14. Barnes JM, Barnes NM, Champaneria S, Costall B, Naylor RJ (1990) Characterization and autoradiographic localisation of 5-HT3 receptor recognition sites identified with [3H]-(S)-zacopride in the forebrain of the rat. Neuropharmacology 29:1037–1045PubMedGoogle Scholar
  15. Barnes NM, Sharp T (1999) A review of central 5-HT receptors and their function. Neuropharmacology 38:1083–1152PubMedGoogle Scholar
  16. Barnes NM, Hales TG, Lummis SC, Peters JA (2009) The 5-HT3 receptor—the relationship between structure and function. Neuropharmacology 56:273–284PubMedGoogle Scholar
  17. Baxter G, Kennett G, Blaney F, Blackburn T (1995) 5-HT2 receptor subtypes: a family re-united? Trends Pharmacol Sci 16:105–110PubMedGoogle Scholar
  18. Beart PM, McDonald D (1982) 5-Hydroxytryptamine and 5-hydroxytryptaminergic-dopaminergic interactions in the ventral tegmental area of rat brain. J Pharm Pharmacol 34:591–593PubMedGoogle Scholar
  19. Bender E, Pindon A, van Oers I, Zhang YB, Gommeren W, Verhasselt P, Jurzak M, Leysen J, Luyten W (2000) Structure of the human serotonin 5-HT4 receptor gene and cloning of a novel 5-HT4 splice variant. J Neurochem 74:478–489PubMedGoogle Scholar
  20. Benloucif S, Galloway MP (1991) Facilitation of dopamine release in vivo by serotonin agonists: studies with microdialysis. Eur J Pharmacol 200:1–8PubMedGoogle Scholar
  21. Benloucif S, Keegan MJ, Galloway MP (1993) Serotonin-facilitated dopamine release in vivo: pharmacological characterization. J Pharmacol Exp Ther 265:373–377PubMedGoogle Scholar
  22. Bentué-Ferrer D, Reymann JM, Rousselle JC, Massot O, Bourin M, Allain H, Fillion G (1998) 5-HT-moduline, a 5-HT(1B/1D) receptor endogenous modulator, interacts with dopamine release measured in vivo by microdialysis. Eur J Pharmacol 358:129–137PubMedGoogle Scholar
  23. Benuck M, Reith MEA (1992) Dopamine releasing effect of phenylbiguanide in rat striatal slices. Naunyn-Schmiedeberg’s Arch Pharmacol 345:666–672Google Scholar
  24. Benwell ME, Balfour DJ, Lucchi HM (1993) Influence of tetrodotoxin and calcium on changes in extracellular dopamine levels evoked by systemic nicotine. Psychopharmacology (Berl) 112:467–474Google Scholar
  25. Berge OG, Chacho D, Hole K (1983) Inhibitory effect of 5-methoxy-N,N-dimethyltryptamine on the synaptosomal uptake of 5-hydroxytryptamine. Eur J Pharmacol 90:293–296PubMedGoogle Scholar
  26. Berger UV, Gu XF, Azmitia EC (1992) The substituted amphetamines 3,4-methylenedioxymethamphetamine, methamphetamine, p-chloroamphetamine and fenfluramine induce 5-hydroxytryptamine release via a common mechanism blocked by fluoxetine and cocaine. Eur J Pharmacol 215:153–160PubMedGoogle Scholar
  27. Besson MJ, Chéramy A, Feltz P, Glowinski J (1969) Release of the newly synthesized dopamine from dopamine-containing terminals in the striatum of the rat. Proc Natl Acad Sci USA 62:741–748PubMedGoogle Scholar
  28. Blandina P, Goldfarb J, Craddock-Royal B, Green JP (1989) Release of endogenous dopamine by stimulation of 5-HT3 receptors in rat striatum. J Pharmacol Exp Ther 251:803–809PubMedGoogle Scholar
  29. Blondel O, Gastineau M, Dahmoune Y, Langlois M, Fischmeister RJ (1998) Cloning, expression, and pharmacology of four human 5-hydroxytryptamine 4 receptor isoforms produced by alternative splicing in the carboxyl terminus. J Neurochem 70:2252–2261PubMedGoogle Scholar
  30. Bobillier P, Seguin S, Petitjean F, Salvert D, Touret M, Jouvet M (1976) The raphe nuclei of the cat brain-stem: a topographical atlas of their efferent projections as revealed by autoradiography. Brain Res 113:449–486PubMedGoogle Scholar
  31. Bockaert J, Sebben M, Dumuis A (1990) Pharmacological characterization of 5-HT4 receptors positively coupled to adenylate cyclase in adult guinea pig hippocampal membranes: effect of substituted benzamide derivatives. Mol Pharmacol 37:408–411PubMedGoogle Scholar
  32. Bonaventure P, Voorn P, Luyten WH, Jurzak M, Schotte A, Leysen JE (1998) Detailed mapping of serotonin 5-HT1B and 5-HT1D receptor messenger RNA and ligand binding sites in guinea-pig brain and trigeminal ganglion: clues for function. Neuroscience 82:469–484PubMedGoogle Scholar
  33. Bonaventure P, Hall H, Gommeren W, Cras P, Langlois X, Jurzak M, Leysen JE (2000) Mapping of serotonin 5-HT4 receptor mRNA and ligand binding sites in the post-mortem human brain. Synapse 36:35–46PubMedGoogle Scholar
  34. Bonhomme N, De Deurwaerdère P, Le Moal M, Spampinato U (1995) Evidence for 5-HT4 receptor subtype involvement in the enhancement of striatal dopamine release induced by serotonin: a microdialysis study in the halothane-anesthetized rat. Neuropharmacology 34:269–279PubMedGoogle Scholar
  35. Bonsi P, Cuomo D, Ding J, Sciamanna G, Ulrich S, Tscherter A, Bernardi G, Surmeier DJ, Pisani A (2007) Endogenous serotonin excites striatal cholinergic interneurons via the activation of 5-HT2C, 5-HT6, and 5-HT7 serotonin receptors: implications for extrapyramidal side effects of serotonin reuptake inhibitors. Neuropsychopharmacology 32:1840–1854PubMedGoogle Scholar
  36. Boschert U, Amara DA, Segu L, Hen R (1994) The mouse 5-hydroxytryptamine 1B receptor is localized predominantly on axon terminals. Neuroscience 58:167–182PubMedGoogle Scholar
  37. Bourson A, Boess FG, Bös M, Sleight AJ (1998) Involvement of 5-HT6 receptors in nigro-striatal function in rodents. Br J Pharmacol 125:1562–1566PubMedGoogle Scholar
  38. Bowyer JF, Masserano JM, Weiner N (1987) Inhibitory effects of amphetamine on potassium-stimulated release of [3H]dopamine from striatal slices and synaptosomes. J Pharmacol Exp Ther 240:177–186PubMedGoogle Scholar
  39. Bruinvels AT, Palacios JM, Hoyer D (1993) 5-Hydroxytryptamine1 recognition sites in rat brain: heterogeneity of non-5-hydroxytryptamine1A/1C binding sites revealed by quantitative receptor autoradiography. Neuroscience 53:465–473PubMedGoogle Scholar
  40. Bruinvels AT, Landwehrmeyer B, Gustafson EL, Durkin MM, Mengod G, Branchek TA, Hoyer D, Palacios JM (1994) Localization of 5-HT1B, 5-HT1D alpha, 5-HT1E and 5-HT1F receptor messenger RNA in rodent and primate brain. Neuropharmacology 33:367–386PubMedGoogle Scholar
  41. Bubar MJ, Cunningham KA (2007) Distribution of serotonin 5-HT2C receptors in the ventral tegmental area. Neuroscience 146:286–297PubMedGoogle Scholar
  42. Bubser M, Backstrom JR, Sanders-Bush E, Roth BL, Deutch AY (2001) Distribution of serotonin 5-HT2A receptors in afferents of the rat striatum. Synapse 39:297–304PubMedGoogle Scholar
  43. Bunin MA, Wightman RM (1998) Quantitative evaluation of 5-hydroxytryptamine (serotonin) neuronal release and uptake: an investigation of extrasynaptic transmission. J Neurosci 18:4854–4860PubMedGoogle Scholar
  44. Bunney EB, Appel SB, Brodie MS (2000) Cocaine potentiates ethanol-induced excitation of dopaminergic reward neurons in the ventral tegmental area. J Pharmacol Exp Ther 293:383–389PubMedGoogle Scholar
  45. Burnet PWJ, Eastwood SL, Lacey K, Harrison PJ (1995) The distribution of 5-HT1A and 5-HT2A receptor mRNA in human brain. Brain Res 676:157–168PubMedGoogle Scholar
  46. Butcher LL, Engel J, Fuxe K (1972) Behavioral, biochemical, and histochemical analyses of the central effects of monoamine precursors after peripheral decarboxylase inhibition. Brain Res 41:387–411PubMedGoogle Scholar
  47. Carboni E, Acquas E, Frau R, Di Chiara G (1989) Differential inhibitory effects of a 5-HT3 antagonist on drug-induced stimulation of dopamine release. Eur J Pharmacol 164:515–519PubMedGoogle Scholar
  48. Carta M, Carlsson T, Kirik D, Bjorklund A (2007) Dopamine released from 5-HT terminals is the cause of l-DOPA-induced dyskinesia in parkinsonian rats. Brain 130:1819–1833PubMedGoogle Scholar
  49. Cheramy A, Leviel V, Glowinski J (1981) Dendritic release of dopamine in the substantia nigra. Nature 289:537–542PubMedGoogle Scholar
  50. Clemett DA, Punhani T, Duxon MS, Blackburn TP, Fone KC (2000) Immunohistochemical localisation of the 5-HT2C receptor protein in the rat CNS. Neuropharmacology 39:123–132PubMedGoogle Scholar
  51. Compan V, Daszuta A, Salin P, Sebben M, Bockaert J, Dumuis A (1996) Lesion study of the distribution of serotonin 5-HT4 receptors in rat basal ganglia and hippocampus. Eur J Neurosci 8:2591–2598PubMedGoogle Scholar
  52. Compan V, Segu L, Buhot MC, Daszuta A (1998) Selective increases in serotonin 5-HT1B/1D and 5-HT2A/2C binding sites in adult rat basal ganglia following lesions of serotonergic neurons. Brain Res 793:103–111PubMedGoogle Scholar
  53. Cornea-Hébert V, Riad M, Wu C, Singh SK, Descarries L (1999) Cellular and subcellular distribution of the serotonin 5-HT2A receptor in the central nervous system of adult rat. J Comp Neurol 409:187–209PubMedGoogle Scholar
  54. D’Amato RJ, Largent BL, Snowman AM, Snyder SH (1987) Selective labeling of serotonin uptake sites in rat brain by [3H]citalopram contrasted to labeling of multiple sites by [3H]imipramine. J Pharmacol Exp Ther 242:364–371PubMedGoogle Scholar
  55. Davies PA, Pistis M, Hanna MC, Peters JA, Lambert JJ, Hales TG, Kirkness EF (1999) The 5-HT3B subunit is a major determinant of serotonin-receptor function. Nature 397:359–363PubMedGoogle Scholar
  56. De Belleroche JS, Bradford HF (1980) Presynaptic control of the synthesis and release of dopamine from striatal synaptosomes: a comparison between the effects of 5-hydroxytryptamine, acetylcholine and glutamate. J Neurochem 35:1227–1234PubMedGoogle Scholar
  57. De Deurwaerdère P, Bonhomme N, Le Moal M, Spampinato U (1995) d-Fenfluramine enhances striatal dopamine release in vivo by a mechanism independent of serotonergic nerve endings and dopaminergic uptake sites. J Neurochem 65:1100–1108PubMedGoogle Scholar
  58. De Deurwaerdère P, Bonhomme N, Lucas G, Le Moal M, Spampinato U (1996) Serotonin enhances striatal dopamine outflow in vivo through dopamine uptake sites. J Neurochem 66:210–215PubMedGoogle Scholar
  59. De Deurwaerdère P, L’hirondel M, Bonhomme N, Lucas G, Chéramy A, Spampinato U (1997) Serotonin stimulation of 5-HT4 receptors indirectly enhances dopamine release in the rat striatum. J Neurochem 68:195–203PubMedGoogle Scholar
  60. De Deurwaerdère P, Stinus L, Spampinato U (1998) Opposite change of in vivo dopamine release in the rat nucleus accumbens and striatum that follows electrical stimulation of dorsal raphe nucleus: role of 5-HT3 receptors. J Neurosci 18:6528–6538PubMedGoogle Scholar
  61. De Deurwaerdère P, Cervo L, Stinus L, Spampinato U (2002) Central 5-HT4 receptors and dopamine-dependent motor behaviors: searching for a functional role. Pharmacol Biochem Behav 71:627–633PubMedGoogle Scholar
  62. De Deurwaerdère P, Navailles S, Berg KA, Clarke WP, Spampinato U (2004) Constitutive activity of serotonin2C receptor inhibits in vivo dopamine release in the rat nucleus accumbens and striatum. J Neurosci 24:3235–3241PubMedGoogle Scholar
  63. De Deurwaerdère P, Moison D, Navailles S, Porras G, Spampinato U (2005) Regionally and functionally distinct serotonin3 receptors control in vivo dopamine outflow in the rat nucleus accumbens. J Neurochem 94:140–149PubMedGoogle Scholar
  64. De Deurwaerdère P, Le Moine C, Chesselet MF (2010) Selective blockade of serotonin2C receptor enhances Fos expression specifically in the striatum and the subthalamic nucleus within the basal ganglia. Neurosci Lett 469:251–255PubMedGoogle Scholar
  65. De Groote L, Olivier B, Westenberg HG (2003) Role of 5-HT1B receptors in the regulation of extracellular serotonin and dopamine in the dorsal striatum of mice. Eur J Pharmacol 476:71–77PubMedGoogle Scholar
  66. de Langen CD, Stoof JC, Mulder AH (1979) Studies on the nature of the releasable pool of dopamine in synaptosomes from rat corpus striatum: depolarization-induced release of 3H-dopamine from superfused synaptosomes labelled under various conditions. Naunyn-Schmiedeberg’s Arch Pharmacol 308:41–49Google Scholar
  67. De Simoni MG, Dal Toso G, Froditto F, Sokola A, Algeri S (1987) Modulation of striatal metabolism by the activity of dorsal raphe serotonergic afferences. Brain Res 411:81–88PubMedGoogle Scholar
  68. Descarries L, Mechawar N (2000) Ultrastructural evidence for diffuse transmission by monoamine and acetylcholine neurons of the central nervous system. Prog Brain Res 125:27–47PubMedGoogle Scholar
  69. Descarries L, Seguela P, Watkins KC (1991) Nonjunctional relationships of monoamine axon terminals in the cerebral cortex of adult rat. In: Fuxe K, Agnati LF (eds) Volume transmission in the brain: novel mechanisms for neural transmission. Raven, New York, pp 53–62Google Scholar
  70. Deutch AY, Moghaddam B, Innis RB, Krystal JH, Aghajanian GK, Bunney BS, Charney DS (1991) Mechanisms of action of atypical antipsychotic drugs: implications for novel therapeutic strategies for schizophrenia. Schizophr Res 4:21–156Google Scholar
  71. Dewar KM, Reader TA, Grondin L, Descarries L (1991) [3H]paroxetine binding and serotonin content of rat and rabbit cortical areas, hippocampus, neostriatum, ventral mesencephalic tegmentum, and midbrain raphe nuclei region. Synapse 9:14–26PubMedGoogle Scholar
  72. Dewey SL, Smith GS, Logan J, Alexof D, Ding Y, King P, Pappas N, Brodie JD, Ashby CR (1995) Serotonergic modulation of striatal dopamine measured with positon emission tomography (PET) and in vivo microdialysis. J Neurosci 15:821–829PubMedGoogle Scholar
  73. Di Chiara G (1990) In vivo brain dialysis of neurotransmitters. Trends Pharmacol Sci 11:116–121PubMedGoogle Scholar
  74. Di Chiara G, Imperato A (1988) Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci USA 85:5274–5278PubMedGoogle Scholar
  75. Di Chiara G, Tanda GL, Frau R, Carboni E (1992) Heterologous monoamine reuptake: lack of transmitter specificity of neuron-specific carriers. Neurochem Int 20:231S–235SPubMedGoogle Scholar
  76. Di Giovanni G, De Deurwaerdère P, Di Mascio M, Di Matteo V, Esposito E, Spampinato U (1999) Selective blockade of serotonin2B/2C receptors enhances mesolimbic and mesostriatal dopaminergic function: a combined in vivo electrophysiological and microdialysis study. Neuroscience 91:587–597PubMedGoogle Scholar
  77. Di Giovanni G, Di Matteo V, Pierucci M, Esposito E (2008) Serotonin–dopamine interaction: electrophysiological evidence. Prog Brain Res 172:45–71PubMedGoogle Scholar
  78. Di Matteo V, Pierucci M, Esposito E (2004) Selective stimulation of serotonin2c receptors blocks the enhancement of striatal and accumbal dopamine release induced by nicotine administration. J Neurochem 89:418–429PubMedGoogle Scholar
  79. Di Matteo V, Pierucci M, Esposito E, Crescimanno G, Benigno A, Di Giovanni G (2008) Serotonin modulation of the basal ganglia circuitry: therapeutic implication for Parkinson’s disease and other motor disorders. Prog Brain Res 172:423–463PubMedGoogle Scholar
  80. Doménech T, Beleta J, Palacios JM (1997) Characterization of human serotonin 1D and 1B receptors using [3H]-GR-125743, a novel radiolabelled serotonin 5HT1D/1B receptor antagonist. Naunyn-Schmiedeberg’s Arch Pharmacol 356:328–334Google Scholar
  81. Doucet E, Miquel MC, Nosjean A, Vergé D, Hamon M, Emerit MB (2000) Immunolabeling of the rat central nervous system with antibodies partially selective of the short form of the 5-HT3 receptor. Neuroscience 95:881–892PubMedGoogle Scholar
  82. Dremencov E, Newman ME, Kinor N, Blatman-Jan G, Schindler CJ, Overstreet DH, Yadid G (2005) Hyperfunctionality of serotonin-2C receptor-mediated inhibition of accumbal dopamine release in an animal model of depression is reversed by antidepressant treatment. Neuropharmacology 48:34–42PubMedGoogle Scholar
  83. Dugast C, Suaud-Chagny MF, Gonon F (1994) Continuous in vivo monitoring of evoked dopamine release in the rat nucleus accumbens by amperometry. Neuroscience 62:647–654PubMedGoogle Scholar
  84. Dumuis A, Bouhehal R, Sebben M, Cory R, Bockaert J (1988) A nonclassical 5-hydroxytryptamine receptor positively coupled with adenylate cyclase in the central nervous system. Mol Pharmacol 34:880–887PubMedGoogle Scholar
  85. Dumuis A, Sebben M, Bockaert BRL (1989) BRL 24924: a potent agonist at a non-classical 5-HT receptor positively coupled with adenylate cyclase in colliculi neurons. J Eur Pharmacol 162:381–384Google Scholar
  86. Duxon MS, Flanigan TP, Reavley AC, Baxter GS, Blackburn TP, Fone KC (1997) Evidence for expression of the 5-hydroxytryptamine-2B receptor protein in the rat central nervous system. Neuroscience 76:323–329PubMedGoogle Scholar
  87. Eberle-Wang K, Mikeladze Z, Uryu K, Chesselet MF (1997) Pattern of expression of the serotonin2C receptor messenger RNA in the basal ganglia of adult rats. J Comp Neurol 384:233–247PubMedGoogle Scholar
  88. Egerton A, Ahmad R, Hirani E, Grasby PM (2008) Modulation of striatal dopamine release by 5-HT2A and 5-HT2C receptor antagonists: [11C]raclopride PET studies in the rat. Psychopharmacology (Berl) 200:487–496Google Scholar
  89. El Ayadi A, Afailal I, Errami M (2001) Effects of voltage-sensitive calcium channel blockers on extracellular dopamine levels in rat striatum. Metab Brain Dis 16:121–131PubMedGoogle Scholar
  90. Engel G, Göthert M, Hoyer D, Schlicker E, Hillenbrand K (1986) Identity of inhibitory presynaptic 5-hydroxytryptamine (5-HT) autoreceptors in the rat brain cortex with 5-HT1B binding sites. Naunyn-Schmiedeberg’s Arch Pharmacol 332:1–7Google Scholar
  91. Ennis C, Kemp JD, Cox B (1981) Characterization of inhibitory 5-hydroxytryptamine receptors that modulate dopamine release in the striatum. J Neurochem 36:1515–1520PubMedGoogle Scholar
  92. Erlander MG, Lovenberg TW, Baron BM, de Lecea L, Danielson PE, Racke M, Slone AL, Siegel BW, Foye PE, Cannon K, Burns JE, Sutcliffe JG (1993) Two members of a distinct subfamily of 5-hydroxytryptamine receptors differentially expressed in rat brain. Proc Natl Acad Sci USA 90:3452–3456PubMedGoogle Scholar
  93. Ferré S, Cortés R, Artigas F (1994) Dopaminergic regulation of the serotonergic raphe-striatal pathway: microdialysis studies in freely moving rats. J Neurosci 14:4839–4846PubMedGoogle Scholar
  94. Feuerstein TJ, Hertting G, Lupp A, Neufang B (1986) False labelling of dopaminergic terminals in the rabbit caudate nucleus: uptake and release of [3H]-5-hydroxytryptamine. Br J Pharmacol 88:677–684PubMedGoogle Scholar
  95. Fink KB, Göthert M (2007) 5-HT receptor regulation of neurotransmitter release. Pharmacol Rev 59:360–417PubMedGoogle Scholar
  96. Fox SH, Brotchie JM (2000) 5-HT2C receptor binding is increased in the substantia nigra pars reticulata in Parkinson’s disease. Mov Disord 15:1064–1069PubMedGoogle Scholar
  97. Frankel PS, Harlan RE, Garcia MM (1998) The 5-HT3 receptor antagonist, MDL 72222, dose dependently potentiates morphine-induced immediate-early gene expression in the caudate putamen. Brain Res 814:186–193PubMedGoogle Scholar
  98. Frechilla D, Cobreros A, Saldise L, Moratalla R, Insausti R, Luquin M, Del Río J (2001) Serotonin 5-HT1A receptor expression is selectively enhanced in the striosomal compartment of chronic parkinsonian monkeys. Synapse 39:288–296PubMedGoogle Scholar
  99. Fujita S, Kiguchi M, Lee J, Terakado M, Suga K, Hatanaka H, Koshikawa N (2008) 5-HT1A and 5-HT1B receptors in the ventrolateral striatum differentially modulate apomorphine-induced jaw movements in rats. J Oral Sci 50:387–395PubMedGoogle Scholar
  100. Gallager DW, Sanders-Bush E, Aghajanian GK, Sulser F (1975) An evaluation of the use of intraventricularly administered [3H]-5-hydroxytryptamine as a marker for endogenous brain 5-hydroxytryptamine. Brain Res 93:111–122PubMedGoogle Scholar
  101. Galloway MP, Suchowski C, Keegan MJ, Hjorth S (1993) Local infusion of the selective 5-HT1B agonist CP-93,129 facilitates striatal dopamine release in vivo. Synapse 15:90–92PubMedGoogle Scholar
  102. Ge J, Barnes NM (1996) 5-HT4 receptor mediated modulation of 5-HT release in the rat hippocampus in vivo. Brain J Pharmacol 117:1475–1480Google Scholar
  103. Gerald C, Adham N, Kao H-T, Olsen MA, Laz TM, Schechter LE, Bard JA, Vaysse PJ-J, Hartig PR, Branchek TA, Weinshank LW (1995) The 5-HT4 receptor: molecular cloning and pharmacological characterization of two splice variants. EMBO J 14:2806–2815PubMedGoogle Scholar
  104. Gérard C, el Mestikawy SE, Lebrand C, Adrien J, Ruat M, Traiffort E, Hamon M, Martres M-P (1996) Quantitative RT-PCR distribution of serotonin 5-HT6 receptor mRNA in the central nervous system of control or 5,7-dihydroxytryptamine-treated rats. Synapse 23:164–173PubMedGoogle Scholar
  105. Gérard C, Martres MP, Lefèvre K, Miquel MC, Vergé D, Lanfumey L, Doucet E, Hamon M, el Mestikawy SE (1997) Immuno-localization of serotonin 5-HT6 receptor-like material in the rat central nervous system. Brain Res 746:207–219PubMedGoogle Scholar
  106. Gerfen CR (1984) The neostriatal mosaic: compartmentalization of corticostriatal input and striatonigral output systems. Nature 311:461–464PubMedGoogle Scholar
  107. Gerfen CR (1985) The neostriatal mosaic. I. Compartmental organization of projections from the striatum to the substantia nigra in the rat. J Comp Neurol 236:454–476PubMedGoogle Scholar
  108. Gerfen CR (1987) The neostriatal mosaic: II. Patch- and matrix-directed mesostriatal dopaminergic and non-dopaminergic systems. J Neurosci 7:3915–3934PubMedGoogle Scholar
  109. Giambalvo CT, Snodgrass SR (1978) Biochemical and behavioral effects of serotonin neurotoxins on the nigrostriatal dopamine system: comparison of injection sites. Brain Res 152:555-566PubMedGoogle Scholar
  110. Gozlan H, El Mestikawi S, Pichat L, Glowinski J, Hamon M (1983) Identification of presynaptic serotonin autoreceptors using a new ligand: 3H-PAT. Nature (Lond) 305:40–142Google Scholar
  111. Graybiel AM (1991) Basal ganglia—input, neural activity, and relation to the cortex. Curr Opin Neurobiol 1:644–651PubMedGoogle Scholar
  112. Graybiel AM (2005) The basal ganglia: learning new tricks and loving it. Curr Opin Neurobiol 15:638–644PubMedGoogle Scholar
  113. Grossman CJ, Kilpatrick GJ, Bunce KT (1993) Development of a radioligand binding assay for 5-HT4 receptors in guinea-pig and rat brain. Br J Pharmacol 109:618–624PubMedGoogle Scholar
  114. Gudelsky GA, Yamamoto BK (2008) Actions of 3,4-methylenedioxymethamphetamine (MDMA) on cerebral dopaminergic, serotonergic and cholinergic neurons. Pharmacol Biochem Behav 90:198–207PubMedGoogle Scholar
  115. Hall H, Lundkvist C, Halldin C, Farde L, Pike VW, McCarron JA, Fletcher A, Cliffe IA, Barf T, Wikstrom H, Sedvall G (1997) Autoradiographic localization of 5-HT1A receptors in the post-mortem human brain using [3H]WAY-100635 and [11C]WAY-100635. Brain Res 745:96–108PubMedGoogle Scholar
  116. Hållbus M, Magnusson T, Magnusson O (1997) Influence of 5-HT1B/1D receptors on dopamine release in the guinea pig nucleus accumbens: a microdialysis study. Neurosci Lett 225:57–60PubMedGoogle Scholar
  117. Hamon M, Lanfumey L, el Mestikawy S, Boni C, Miquel MC, Bolaños F, Schechter L, Gozlan H (1990) The main features of central 5-HT1 receptors. Neuropsychopharmacology 3:349–360PubMedGoogle Scholar
  118. Hamon M, Doucet E, Lefevre K, Miquel MC, Lanfumey L, Insausti R, Frechilla D, Del Rio J, Verge D (1999) Antibodies and antisense oligonucleotide for probing the distribution and putative functions of central 5-HT6 receptors. Neuropsychopharmacology 21:68S–76SPubMedGoogle Scholar
  119. Heidmann DEA, Metcalf MA, Kohen R, Hamblin MW (1997) Four 5-hydroxytryptamine7 (5-HT7) receptor isoforms in human and rats produced by alternative splicing: species differences due to altered intron–exon organization. J Neurochem 68:1372–1381PubMedGoogle Scholar
  120. Hen R (1992) Of mice and flies: commonalities among 5-HT receptors. Trends Pharmacol Sci 13:160–165PubMedGoogle Scholar
  121. Herdon H, Strupish J, Nahorski SR (1985) Differences between the release of radiolabelled and endogenous dopamine from superfused rat brain slices: effect of depolarizing stimuli, amphetamine and synthesis inhibition. Brain Res 348:309–320PubMedGoogle Scholar
  122. Hoyer D, Clarke DE, Fozard JR, Hartig PR, Martin GR, Mylecharane EJ, Saxena PR, Humphrey PPA (1994) VII. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol Rev 46:157–203PubMedGoogle Scholar
  123. Hoyer D, Hannon JP, Martin GR (2002) Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol Biochem Behav 71:533–554PubMedGoogle Scholar
  124. Hrdina PD, Foy B, Hepner A, Summers RJ (1990) Antidepressant binding sites in brain: autoradiographic comparison of [3H]paroxetine and [3H]imipramine localization and relationship to serotonin transporter. J Pharmacol Exp Ther 252:410–418PubMedGoogle Scholar
  125. Ichikawa J, Meltzer HY (1995) Effect of antidepressants on striatal and accumbens extracellular dopamine levels. Eur J Pharmaco 281:255–261Google Scholar
  126. Imperato A, Angelucci L (1989) 5-HT3 receptors control dopamine release in the nucleus accumbens of freely-moving rats. Neurosci Lett 101:214–217PubMedGoogle Scholar
  127. Iyer RN, Bradberry CW (1996) Serotonin-mediated increase in prefrontal cortex dopamine release: pharmacological characterization. J Pharmacol Exp Ther 277:40–47PubMedGoogle Scholar
  128. Izenwasser S, Werling LL, Rosenberger JG, Cox BM (1990) Characterization of binding of [3H]GBR 12935 (1-[2-(diphenylmethoxy)ethyl]-4-(3-phenylpropyl)-piperazine) to membranes and to solubilized membrane extracts from terminal field regions of mesolimbic, mesocortical and nigrostriatal dopamine pathways. Neuropharmacology 29:1017–1024PubMedGoogle Scholar
  129. Jackson BP, Wightman RM (1995) Dynamics of 5-hydroxytryptamine released from dopamine neurons in the caudate putamen of the rat. Brain Res 674:163–166PubMedGoogle Scholar
  130. Jacocks HM, Cox BM (1992) Serotonin-stimulated release of (3H)-dopamine via reversal of the dopamine transporter in rat striatum and nucleus accumbens: a comparison with release elicited by potassium, N-methyl-d-aspartic acid, glutamic acid and d-amphetamine. J Pharmacol Exp Ther 262:356–364PubMedGoogle Scholar
  131. Jakeman LB, To ZP, Eglen RM, Wong EHF, Bonhaus DW (1994) Quantitative autoradiography of 5-HT4 receptors in brains of three species using two structurally distinct radioligands, [3H]GR113808 and [3H]BIMU-1. Neuropharmacology 33:1027–1038PubMedGoogle Scholar
  132. Jenner P, Sheehy M, Marsden CD (1983) Noradrenaline and 5-hydroxytryptamine modulation of brain dopamine function: implications for the treatment of Parkinson’s disease. Br J Clin Pharmacol 15:277S–289SPubMedGoogle Scholar
  133. Johnson EA, Tsai CE, Shahan YH, Azzaro AJ (1993) Serotonin 5-HT1A receptors mediate inhibition of tyrosine hydroxylation in rat striatum. J Pharmacol Exp Ther 266:133–141PubMedGoogle Scholar
  134. Johnson EA, Fox JL, Azzaro AJ (1996) The anxiolytic serotonin 5-HT1A receptor agonists buspirone, ipsapirone and gepirone are inhibitors of tyrosine hydroxylation in rat striatum. Behav Brain Res 73:331–335PubMedGoogle Scholar
  135. Jones SR, Gainetdinov RR, Wightman RM, Caron MG (1998) Mechanisms of amphetamine action revealed in mice lacking the dopamine transporter. J Neurosci 18:1979–1986PubMedGoogle Scholar
  136. Kalén P, Strecker RE, Rosengren E, Björklund A (1988) Endogenous release of neuronal serotonin and 5-hydroxyindoleacetic acid in the caudate-putamen of the rat as revealed by intracerebral dialysis coupled to high-performance liquid chromatography with fluorimetric detection. J Neurochem 51:1422–1435PubMedGoogle Scholar
  137. Kamal LA, Arbilla S, Galzin AM, Langer SZ (1983) Amphetamine inhibits the electrically evoked release of [3H]dopamine from slices of the rabbit caudate. J Pharmacol Exp Ther 227:446–458PubMedGoogle Scholar
  138. Kelly E, Jenner P, Marsden CD (1985) Evidence that [3H]dopamine is taken up and released from nondopaminergic nerve terminals in the rat substantia nigra in vitro. J Neurochem 45:137–144PubMedGoogle Scholar
  139. Kidd EJ, Laporte AM, Langlois X, Fattaccini C-M, Doyen C, Lombard MC, Gozlan H, Hamon M (1993) 5-HT3 receptors in the rat central nervous system are mainly located on nerve fibres and terminals. Brain Res 612:289–298PubMedGoogle Scholar
  140. Kilpatrick G, Jones BJ, Tyers MB (1989) Binding of the 5-HT3 ligand, 3H GR 65630, to rat area postrema, vagus nerve and the brains of several species. Eur J Pharmacol 159:157–164PubMedGoogle Scholar
  141. Kirby LG, Kreiss DS, Singh A, Lucki I (1995) Effect of destruction of serotonin neurons on basal and fenfluramine-induced serotonin release in striatum. Synapse 20:99–105PubMedGoogle Scholar
  142. Koch S, Galloway MP (1997) MDMA induced dopamine release in vivo: role of endogenous serotonin. J Neural Transm 104:135–146PubMedGoogle Scholar
  143. Kreiss DF, Wieland S, Lucki I (1993) The presence of a serotonin uptake inhibitor alters pharmacological manipulations of serotonin release. Neuroscience 52:295–301PubMedGoogle Scholar
  144. Kuhr WG, Ewing AG, Near JA, Wightman RM (1985) Amphetamine attenuates the stimulated release of dopamine in vivo. J Pharmacol Exp Ther 232:388–394PubMedGoogle Scholar
  145. Laporte AM, Lima L, Gozlan H, Hamon M (1994) Selective in vivo labelling of brain 5-HT1A receptors by [3H]WAY 100635 in the mouse. Eur J Pharmacol 271:505–514PubMedGoogle Scholar
  146. Laprade N, Radja F, Reader TA, Soghomonian JJ (1996) Dopamine receptor agonists regulate levels of the serotonin 5-HT2A receptor and its mRNA in a subpopulation of rat striatal neurons. J Neurosci 16:3727–3736PubMedGoogle Scholar
  147. Levi G, Raiteri M (1993) Carrier-mediated release of neurotransmitters. Trends Neurosci 16:415–419PubMedGoogle Scholar
  148. Leysen JE, Eens A, Gommeren W, van Gompel P, Wynants J (1988) Identification of nonserotonergic [3H]ketanserin binding sites associated with nerve terminals in rat brain and with platelets; relation with release of biogenic amine metabolites induced by ketanserin- and tetrabenazine-like drugs. J Pharmacol Exp Ther 244:310–321PubMedGoogle Scholar
  149. Lindvall O, Björklund A (1978) Anatomy of the dopaminergic neuron systems in the rat brain. Adv Biochem Psychopharmacol 19:1–23PubMedGoogle Scholar
  150. López-Giménez JF, Vilaró MT, Palacios JM, Mengod G (1998) [3H]MDL 100,907 labels 5-HT2A serotonin receptors selectively in primate brain. Neuropharmacology 37:1147–1158PubMedGoogle Scholar
  151. Lopez-Gimenez JF, Mengod G, Palacios JM, Vilaro MT (1999) Human striosomes are enriched in 5-HT2A receptors: autoradiographical visualization with [3H]MDL 100,907, [125I](±)DOI and [3H]ketanserin. Eur J Neurosci 11:3761–3765PubMedGoogle Scholar
  152. López-Giménez JF, Vilaró MT, Palacios JM, Mengod G (2001) Mapping of 5-HT2A receptors and their mRNA in monkey brain: [3H]MDL 100,907 autoradiography and in situ hybridization studies. J Comp Neurol 429:571–589PubMedGoogle Scholar
  153. Loric S, Launay JM, Colas JF, Maroteaux L (1992) New mouse 5-HT2-like receptor. Expression in brain, heart and intestine. FEBS Lett 312:203–207PubMedGoogle Scholar
  154. Lovenberg TW, Erlander MG, Baron BM, Racke M, Slone AL, Siegel BW, Craft CM, Burns JE, Danielson PE, Sutcliffe JG (1993) Molecular cloning and functional expression of 5-HT1E-like rat and human 5-hydroxytryptamine receptor genes. Proc Natl Acad Sci USA 90:2184–2188PubMedGoogle Scholar
  155. Lucas G, Spampinato U (2000) Role of striatal serotonin2A and serotonin2C receptor subtypes in the control of in vivo dopamine outflow in the rat striatum. J Neurochem 74:693–701PubMedGoogle Scholar
  156. Lucas G, Bonhomme N, De Deurwaerdère P, Le Moal M, Spampinato U (1997) 8-OH-DPAT, a 5-HT1A agonist and ritanserin, a 5-HT2A/C antagonist, reverse haloperidol-induced catalepsy in rats independently of striatal dopamine release. Psychopharmacology 131:57–63PubMedGoogle Scholar
  157. Lucas G, De Deurwaerdère P, Porras G, Spampinato U (2000a) Endogenous serotonin enhances the release of dopamine in the striatum only when nigro-striatal dopaminergic transmission is activated. Neuropharmacology 39:1984–1995PubMedGoogle Scholar
  158. Lucas G, De Deurwaerdère P, Caccia S, Spampinato U (2000b) The effect of serotonergic agents on haloperidol-induced striatal dopamine release in vivo: opposite role of 5-HT2A and 5-HT2C receptor subtypes and significance of the haloperidol dose used. Neuropharmacology 39:1053–1063PubMedGoogle Scholar
  159. Lucas G, Di Matteo V, De Deurwaerdère P, Porras G, Martin-Ruiz R, Artigas F, Esposito E, Spampinato U (2001) Neurochemical and electrophysiological evidence that 5-HT4 receptors exert a state-dependent facilitatory control in vivo on nigrostriatal, but not mesoaccumbal dopaminergic function. Eur J Neurosci 13:889–898PubMedGoogle Scholar
  160. Lupp A, Bär KI, Lücking CH, Feuerstein TJ (1992) Different effects of serotonin (5-HT) uptake blockers in caudate nucleus and hippocampus of the rabbit: role of monoamine oxidase in dopaminergic terminals. Psychopharmacology (Berl) 106:118–126Google Scholar
  161. Luthman J, Friedemann MN, Hoffer BJ, Gerhardt GA (1993) In vivo electrochemical measurements of exogenous dopamine clearance in normal and neonatal 6-hydroxydopamine-treated rat striatum. Exp Neurol 122:273–282Google Scholar
  162. Molineaux SM, Jessell TM, Axel R, Julius D (1989) 5-HT1c receptor is a prominent serotonin receptor subtype in the central nervous system. Proc Natl Acad Sci USA 86:6793–6797PubMedGoogle Scholar
  163. Malgouris C, Flamand F, Doble A (1993) Autoradiographic studies of RP 62203, a potent 5-HT2 receptor antagonist. Pharmacological characterization of [3H]RP 62203 binding in the rat brain. Eur J Pharmacol 233:37–45PubMedGoogle Scholar
  164. Maricq AV, Peterson AS, Brake AJ, Myers RM, Julius D (1991) Primary structure and functional expression of the 5-HT3 receptor, a serotonin-gated ion channel. Science 254:432–437PubMedGoogle Scholar
  165. Martín-Cora FJ, Pazos A (2004) Autoradiographic distribution of 5-HT7 receptors in the human brain using [3H]mesulergine: comparison to other mammalian species. Br J Pharmacol 141:92–104PubMedGoogle Scholar
  166. Melamed E, Zoldan J, Friedberg G, Ziv I, Weizmann A (1996) Involvement of serotonin in clinical features of Parkinson’s disease and complications of l-DOPA therapy. Adv Neurol 69:545–550PubMedGoogle Scholar
  167. Meltzer HY (1999) Treatment of schizophrenia and spectrum disorders: pharmacotherapy, psychosocial treatments, and neurotransmitter interactions. Biol Psychiatry 46:1321–1327PubMedGoogle Scholar
  168. Meltzer HY, Nash JF (1991) Effects of antipsychotic drugs on serotonin receptors. Pharmacol Rev 43:587–604PubMedGoogle Scholar
  169. Mengod G, Nguyen H, Le H, Waeber C, Lubbert H, Palacios JM (1990) The distribution and cellular localisation of the serotonin 1C receptor mRNA in the rodent brain examined by in situ hybridization hystochemistry. Comparison with receptor binding distribution. Neuroscience 35:577–591PubMedGoogle Scholar
  170. Mengod G, Vilaró MT, Raurich A, López-Giménez JF, Cortés R, Palacios JM (1996) 5-HT receptors in mammalian brain: receptor autoradiography and in situ hybridization studies of new ligands and newly identified receptors. Histochem J 28:747–758PubMedGoogle Scholar
  171. Mereu G, Fanni B, Gessa GL (1984) General anesthetics prevent dopaminergic neuron stimulation by neuroleptics. In: Usdin E, Carlsson A, Dahlstrom A, Engel J (eds) Catecholamines: neuropharmacology and central nervous system—theoretical aspects. Liss, New York, pp 353–358Google Scholar
  172. Mignon L, Wolf WA (2007) Postsynaptic 5-HT1A receptor stimulation increases motor activity in the 6-hydroxydopamine-lesioned rat: implications for treating Parkinson’s disease. Psychopharmacology (Berl) 192:49–59Google Scholar
  173. Mikics E, Vas J, Aliczki M, Halasz J, Haller J (2009) Interactions between the anxiogenic effects of CB1 gene disruption and 5-HT3 neurotransmission. Behav Pharmacol 20:265–272PubMedGoogle Scholar
  174. Millan MJ (2006) Multi-target strategies for the improved treatment of depressive states: conceptual foundations and neuronal substrates, drug discovery and therapeutic application. Pharmacol Ther 110:135–370PubMedGoogle Scholar
  175. Millan MJ, Brocco M, Gobert A, Joly F, Bervoets K, Rivet JM, Newman-Tancredi A, Audinot V, Maurel S (1999) Contrasting mechanisms of action and sensitivity to antipsychotics of phencyclidine versus amphetamine: importance of nucleus accumbens 5-HT2A sites for PCP-induced locomotion in the rat. Eur J Neurosci 11:4419–4432PubMedGoogle Scholar
  176. Mink JW (1996) The basal ganglia: focused selection and inhibition of competing motor programs. Prog Neurobiol 50:381–425PubMedGoogle Scholar
  177. Miyake A, Mochizuki S, Takemoto Y, Akuzawa S (1995) Molecular cloning of human 5-hydroxytryptamine3 receptor: heterogeneity in distribution and function among species. Mol Pharmacol 48:407–416PubMedGoogle Scholar
  178. Moison D, De Deurwaerdère P, Cagnotto A, Marrazzo A, Prezzavento O, Ronsisvalle G, Mennini T, Spampinato U (2003) Intrastriatal administration of sigma ligands inhibits striatal dopamine release in vivo. Neuropharmacology 45:945–953PubMedGoogle Scholar
  179. Monsma FJ Jr, Shen Y, Ward RP, Hamblin MW, Sibley DR (1993) Cloning and expression of a novel serotonin receptor whith high affinity for tricyclic psychotropic drugs. Mol Pharmacol 43:320–327PubMedGoogle Scholar
  180. Morales M, Bloom FE (1997) The 5-HT3 receptor is present in different subpopulations of GABAergic neurons in the rat telencephalon. J Neurosci 17:3157–3167PubMedGoogle Scholar
  181. Morales M, Wang S-D (2002) Differential composition of 5-hydroxytryptamine3 receptors synthesized in the rat CNS and peripheral nervous system. J Neurosci 22:6732–6741PubMedGoogle Scholar
  182. Morales M, Battenberg E, De Lecea L, Sanna PP, Bloom FE (1996) Cellular and subcellular immunolocalization of the type 3 serotonin receptor in the rat central nervous system. Mol Brain Res 36:251–260PubMedGoogle Scholar
  183. Morilak DA, Garlow SJ, Ciaranello RD (1993) Immunocytochemical localization and description of neurons expressing serotonin2 receptors in the rat brain. Neuroscience 54:701–717PubMedGoogle Scholar
  184. Moukhles H, Bosler O, Bolam JP, Vallée A, Umbriaco D, Geffard M, Doucet G (1997) Quantitative and morphometric data indicate precise cellular interactions between serotonin terminals and postsynaptic targets in rat substantia nigra. Neuroscience 76:1159–1171PubMedGoogle Scholar
  185. Muneoka KT, Takigawa M (2003) 5-Hydroxytryptamine7 (5-HT7) receptor immunoreactivity-positive ‘stigmoid body’-like structure in developing rat brains. Int J Dev Neurosci 21:133–143PubMedGoogle Scholar
  186. Muramatsu M, Tamaki-Ohashi J, Usuki C, Araki H, Chaki S, Aihara H (1988) 5-HT2 antagonists and minaprine block the 5-HT-induced inhibition of dopamine release from rat striatal slices. Eur J Pharmacol 153:89–95PubMedGoogle Scholar
  187. Nash F (1990) Ketanserin pretreatment attenuates MDMA-induced dopamine release in the striatum as measured by in vivo microdialysis. Life Sci 47:2401-2408PubMedGoogle Scholar
  188. Nash F, Brodkin J (1991) Microdialysis studies on 3,4-methylenedioxymethamphetamine-induced DA release: effect of DA uptake inhibitors. J Pharmacol Exp Ther 259:820–825PubMedGoogle Scholar
  189. Navailles S, De Deurwaerdère P (2011) The constitutive activity of 5-HT2C receptors as an additional modality of interaction of the serotonergic system. In 5-HT2C Receptors in the Pathophysiology of CNS Disease. Di Giovanni G, Esposito E, Vincenzo M (eds) Series: The Receptors, vol 22, first eds. Springer, Humana PressGoogle Scholar
  190. Navailles S, De Deurwaerdère P, Porras G, Spampinato U (2004) In vivo evidence that 5-HT2C receptor antagonist but not agonist modulates cocaine-induced dopamine outflow in the rat nucleus accumbens and striatum. Neuropsychopharmacology 29:319–326PubMedGoogle Scholar
  191. Navailles S, Moison D, Ryczko D, Spampinato U (2006) Region-dependent regulation of mesoaccumbens dopamine neurons in vivo by the constitutive activity of central serotonin2C receptors. J Neurochem 99:1311–1319PubMedGoogle Scholar
  192. Navailles S, Bioulac B, Gross C, De Deurwaerdère P (2010) Serotonergic neurons mediate an ectopic release of dopamine in a rat model of Parkinson’s disease. Neurobiol Dis 38:136–143PubMedGoogle Scholar
  193. Narita N, Hashimoto K, Tomitaka S-I, Minabe Y (1996) Interaction of selective serotonin reuptake inhibitors with subtypes of σ receptors in the rat brain. Eur J Pharmacol 307:117–119PubMedGoogle Scholar
  194. Neumaier JF, Sexton TJ, Yracheta J, Diaz AM, Brownfield M (2001) Localization of 5-HT7 receptors in rat brain by immunocytochemistry, in situ hybridization, and agonist stimulated cFos expression. J Chem Neuroanat 21:63–73PubMedGoogle Scholar
  195. Ng LK, Chase TN, Colburn RW, Kopin IJ (1972) l-DOPA in parkinsonism. A possible mechanism of action. Neurology 22:688–696PubMedGoogle Scholar
  196. Ng NK, Lee HS, Wong PT (1999) Regulation of striatal dopamine release through 5-HT1 and 5-HT2 receptors. J Neurosci Res 55:600–607PubMedGoogle Scholar
  197. Numan S, Lundgren KH, Wright DE, Herman JP, Seroogy KB (1995) Increased expression of 5HT2 receptor mRNA in rat striatum following 6-OHDA lesions of the adult nigrostriatal pathway. Brain Res Mol Brain Res 29:391–396PubMedGoogle Scholar
  198. Nurse B, Russell VA, Taljaard JJF (1988) Characterization of the effects of serotonin on the release of [3H]dopamine from rat nucleus accumbens and striatal slices. Neurochem Res 13:403–407PubMedGoogle Scholar
  199. Oliver KR, Kinsey AM, Wainwright A, Sirinathsinghji DJ (2000) Localization of 5-ht5A receptor-like immunoreactivity in the rat brain. Brain Res 867:131–142PubMedGoogle Scholar
  200. Pact V, Giduz T (1999) Mirtazapine treats resting tremor, essential tremor, and levodopa-induced dyskinesias. Neurology 53:1154PubMedGoogle Scholar
  201. Parsons LH, Justice JB (1993) Perfusate serotonin increases extracellular dopamine in the nucleus accumbens as measured by in vivo microdialysis. Brain Res 606:195–199PubMedGoogle Scholar
  202. Pasqualetti M, Nardi I, Ladinsky H, Marazziti D, Cassano GB (1996) Comparative anatomical distribution of serotonin 1A, 1D and 2A receptor mRNAs in human brain postmortem. Mol Brain Res 39:223–233PubMedGoogle Scholar
  203. Pasqualetti M, Ori M, Castagna M, Marazziti D, Cassano GB, Nardi I (1999) Distribution and cellular localization of the serotonin type 2C receptor messenger RNA in human brain. Neuroscience 92:601–611PubMedGoogle Scholar
  204. Patel S, Roberts J, Moorman J, Reavill C (1995) Localization of serotonin-4 receptors in the striatonigral pathway in the rat brain. Neuroscience 69:1159–1167PubMedGoogle Scholar
  205. Patterson TA, Schenk JO (1991) Effects of acute and chronic systemic administration of some typical antipsychotic drugs on turnover of dopamine and potassium ion-induced release of dopamine in the striatum of the rat in vivo. Neuropharmacology 30:943–952PubMedGoogle Scholar
  206. Pazos A, Cortés R, Palacios JM (1985) Quantitative autoradiographic mapping of serotonin receptors in the rat brain. II. Serotonin-2 receptors. Brain Res 346:231–249PubMedGoogle Scholar
  207. Perry DC (1990) Autoradiography of [3H]quipazine in rodent brain. Eur J Pharmacol 187:75–85PubMedGoogle Scholar
  208. Pitts DK, Marwah J (1988) Cocaine and central monoaminergic neurotransmission: a review of electrophysiological studies and comparison to amphetamine and antidepressants. Life Sci 42:949–968PubMedGoogle Scholar
  209. Pompeiano M, Palacios JM, Mengod G (1992) Distribution and cellular localization of mRNA coding for 5-HT1A receptor in the rat brain: correlation with receptor binding. J Neurosci 12:440–453PubMedGoogle Scholar
  210. Pompeiano M, Palacios JM, Mengod G (1994) Distribution of the serotonin 5-HT2 receptor family mRNAs: comparison between 5-HT2A and 5-HT2B receptors. Mol Brain Res 23:163–178PubMedGoogle Scholar
  211. Porras G, Di Matteo V, De Deurwaerdère P, Esposito E, Spampinato U (2002a) Central 5-HT4 receptors selectively regulate the impulse-dependent exocytosis of dopamine in the rat striatum: in vivo studies with morphine amphetamine and cocaine. Neuropharmacology 43:1099–1109PubMedGoogle Scholar
  212. Porras G, Di Matteo V, Fracasso C, Lucas G, De Deurwaerdère P, Caccia S, Esposito E, Spampinato U (2002b) 5-HT2A and 5-HT2C/2B receptor subtypes respectively modulate dopamine release induced in vivo by amphetamine and morphine in both the rat nucleus accumbens and striatum. Neuropsychopharmacology 26:311–324PubMedGoogle Scholar
  213. Porras G, De Deurwaerdère P, Moison D, Spampinato U (2003) Conditional involvement of striatal serotonin3 receptors in the control of in vivo dopamine outflow in the rat striatum. Eur J Neurosci 17:771–781PubMedGoogle Scholar
  214. Pouzet B, Didriksen M, Arnt J (2002) Effects of the 5-HT6 receptor antagonist, SB-271046, in animal models for schizophrenia. Pharmacol Biochem Behav 71:635–643PubMedGoogle Scholar
  215. Pozzi L, Trabace L, Invernizzi R, Samanin R (1995) Intranigral GR 113808, a selective 5-HT4 receptor antagonist, attenuates morphine-stimulated dopamine release in the rat striatum. Brain Res 692:265–268PubMedGoogle Scholar
  216. Quirion R, Richard J (1987) Differential effects of selective lesions of cholinergic and dopaminergic neurons on serotonin-type 1 receptors in rat brain. Synapse 1:124–130PubMedGoogle Scholar
  217. Radja F, Laporte A-M, Daval G, Vergé D, Gozlan H, Hamon M (1991) Autoradiography of serotonin receptor subtypes in the central nervous system. Neurochem Int 18:1–15PubMedGoogle Scholar
  218. Radja F, Descarries L, Dewar KM, Reader TA (1993) Serotonin 5-HT1 and 5-HT2 receptors in adult rat brain after neonatal destruction of nigrostriatal dopamine neurons: a quantitative autoradiographic study. Brain Res 606:273–285PubMedGoogle Scholar
  219. Rees S, den Daas I, Foord S, Goodson S, Bull D, Kilpatrick G, Lee M (1994) Cloning and characterisation of the human 5-HT5A serotonin receptor. FEBS Lett 355:242–246PubMedGoogle Scholar
  220. Reynolds GP, Mason SL, Meldrun A, De Keczer S, Parnes H, Eglen RM, Wong EHF (1995) 5-Hydroxytryptamine (5-HT)4 receptors in post mortem human brain tissue: distribution, pharmacology and effects of neurodegenerative diseases. Br J Pharmacol 114:993–998PubMedGoogle Scholar
  221. Roberts JC, Reavill C, East SZ, Harrison PJ, Patel S, Routledge C, Leslie RA (2002) The distribution of 5-HT6 receptors in rat brain: an autoradiographic binding study using the radiolabelled 5-HT6 receptor antagonist [125I]SB-258585. Brain Res 934:49–57PubMedGoogle Scholar
  222. Rothman RB, Baumann MH (2006) Balance between dopamine and serotonin release modulates behavioral effects of amphetamine-type drugs. Ann NY Acad Sci 1074:245–260PubMedGoogle Scholar
  223. Ruat M, Traiffort E, Arrang JM, Tardivel-Lacombe J, Diaz J, Leurs R, Schwartz JC (1993a) A novel rat serotonin (5-HT6) receptor: molecular cloning, localization and stimulation of cAMP accumulation. Biochem Biophys Res Commun 193:268–276PubMedGoogle Scholar
  224. Ruat M, Traiffort E, Leurs R, Tardivel-Lacombe J, Diaz J, Arrang J-M, Schwartz J-C (1993b) Molecular cloning, characterization, and localization of a high-affinity serotonin receptor (5-HT7) activating cAMP formation. Proc Natl Acad Sci 90:8547–8551PubMedGoogle Scholar
  225. Saavedra JM (1977) Distribution of serotonin and synthesizing enzymes in discrete areas of the brain. Fed Proc 36:2134–2141PubMedGoogle Scholar
  226. Santiago M, Machado A, Cano J (1995) 5-HT3 receptor agonist induced carrier-mediated release of dopamine in rat striatum in vivo. Br J Pharmacol 116:1545–1550PubMedGoogle Scholar
  227. Santiago M, Matarredona ER, Machado A, Cano J (1998) Influence of serotoninergic drugs on in vivo dopamine extracellular output in rat striatum. J Neurosci Res 52:591–598PubMedGoogle Scholar
  228. Sarhan H, Fillion G (1999) Differential sensitivity of 5-HT1B auto and heteroreceptors. Naunyn-Schmiedeberg’s Arch Pharmacol 360:382–390Google Scholar
  229. Sarhan H, Cloëz-Tayarani I, Massot O, Fillion MP, Fillion G (1999) 5-HT1B receptors modulate release of [3H]dopamine from rat striatal synaptosomes. Naunyn-Schmiedeberg’s Arch Pharmacol 359:40–47Google Scholar
  230. Sarhan H, Grimaldi B, Hen R, Fillion G (2000) 5-HT1B receptors modulate release of [3H]dopamine from rat striatal synaptosomes: further evidence using 5-HT moduline, polyclonal 5-HT1B receptor antibodies and 5-HT1B receptor knock-out mice. Naunyn-Schmiedeberg’s Arch Pharmacol 361:12–18Google Scholar
  231. Sari Y, Lefèvre K, Bancila M, Quignon M, Miquel MC, Langlois X, Hamon M, Vergé D (1997) Light and electron microscopic imunocytochemical visualisation of 5-HT1B receptors in the rat brain. Brain Res 760:281–286PubMedGoogle Scholar
  232. Sari Y, Miquel MC, Brisorgueil MJ, Ruiz G, Doucet E, Hamon M, Vergé D (1999) Cellular and subcellular localization of 5-hydroxytryptamine1B receptors in the rat central nervous system: immunocytochemical, autoradiographic and lesion studies. Neuroscience 88:899–915PubMedGoogle Scholar
  233. Saudou F, Hen R (1994) 5-HT receptor subtypes: molecular and functional diversity. Med Chem Res 4:16–84Google Scholar
  234. Schiavi GB, Brunet S, Rizzi CA, Ladinski H (1994) Identification of serotonin 5-HT4 recognition sites in the porcine caudate nucleus by radioligand binding. Neuropharmacology 33:543–549PubMedGoogle Scholar
  235. Schmidt CJ, Black CK (1989) The putative 5-HT3 agonist phenylbiguanide induces carrier-mediated release of [3H]dopamine. Eur J Pharmacol 167:309–310PubMedGoogle Scholar
  236. Schmidt JC, Fadayel GM, Sullivan CK, Taylor VL (1992) 5-HT2 receptors exert a state dependent regulation of dopaminergic function: studies with MDL 100,907 and the amphetamine analogue, 3,4-methylenedioxymethamphetamine. Eur J Pharmacol 223:65–74PubMedGoogle Scholar
  237. Schmidt CJ, Kehne JH, Carr AA, Fadayel GM, Humphreys TM, Ketteler HJ, McCloskey TC, Padich RA, Taylor VL, Sorensen SM (1993) Contribution of serotonin neurotoxins to understanding psychiatric disorders: the role of 5-HT2 receptors in schizophrenia and antipsychotic activity. Int Clin Psychopharmacol 8:25–32PubMedGoogle Scholar
  238. Schmidt CJ, Sullivan CK, Fadayel GM (1994) Blockade of striatal 5-hydroxytryptamine2 receptors reduces the increase in extracellular concentrations of dopamine produced by the amphetamine analogue 3,4-methylenedioxymethamphetamine. J Neurochem 62:1382–1389PubMedGoogle Scholar
  239. Schmitz Y, Lee CJ, Schmauss C, Gonon F, Sulzer D (2001) Amphetamine distorts stimulation-dependent dopamine overflow: effects on D2 autoreceptors, transporters, and synaptic vesicle stores. J Neurosci 21:5916–5924PubMedGoogle Scholar
  240. Schoeffter P, Waeber C (1994) 5-Hydroxytryptamine receptors with a 5-HT6 receptor-like profile stimulating adenylyl cyclase activity in pig caudate membranes. Naunyn-Schmiedeberg’s Arch Pharmacol 350:356–360Google Scholar
  241. Schwartz D, Hernandez L, Hoebel BG (1989) Fenfluramine administered systemically or locally increases extracellular serotonin in the lateral hypothalamus as measured by microdialysis. Brain Res 482:261–270PubMedGoogle Scholar
  242. Sebben M, Ansanay H, Bockaert J, Dumuis A (1994) 5-HT6 receptors positively coupled to adenylyl cyclase in striatal neurones in culture. NeuroReport 5:2553–2557PubMedGoogle Scholar
  243. Seiden LS, Sabol KE, Ricaurte GA (1993) Amphetamine: effects on catecholamine systems and behavior. Annu Rev Pharmacol Toxicol 33:639–677PubMedGoogle Scholar
  244. Sharp T, Bramwell SR, Clark D, Grahame-Smith DG (1989) In vivo measurement of extracellular 5-hydroxytryptamine in hippocampus of the anaesthetized rat using microdialysis: changes in relation to 5-hydroxytryptaminergic neuronal activity. J Neurochem 53:234–240PubMedGoogle Scholar
  245. Shaskan EG, Snyder SH (1970) Kinetics of serotonin accumulation into slices from rat brain: relationship to catecholamine uptake. J Pharmacol Exp Ther 175:404–418PubMedGoogle Scholar
  246. Soghomonian JJ, Doucet G, Descarries L (1987) Serotonin innervation in adult rat neostriatum. I. Quantified regional distribution. Brain Res 425:85–100PubMedGoogle Scholar
  247. Soghomonian JJ, Descarries L, Watkins K (1989) Serotonin innervation in adult rat neostriatum. II. Ultrastructural features: a radioautographic and immunocytochemical study. Brain Res 481:67–86PubMedGoogle Scholar
  248. Sorensen SM, Kehne JH, Fadayel GM, Humphreys TM, Ketteler HJ, Sullivan CK, Taylor VL, Schmidt CJ (1993) Characterization of the 5-HT2 receptor antagonist MDL 100,907 as a putative atypical antipsychotic: behavioral, electrophysiological and neurochemical studies. J Pharmacol Exp Ther 266:684–691PubMedGoogle Scholar
  249. Soubrié P (1986) Reconciling the role of central serotonin neurons in human and animal behavior. Behav Brain Sci 9:319–364Google Scholar
  250. Soubrié P, Reisine TD, Glowinski J (1984) Functional aspects of serotonin transmission in the basal ganglia: a review and in vivo approach using the push–pull cannula technique. Neuroscience 13:605–625PubMedGoogle Scholar
  251. Spoont MR (1992) Modulatory role of serotonin in neural information processing: implications for human psychopathology. Psychol Bull 112:330–350PubMedGoogle Scholar
  252. Steinbusch HW (1984) Serotonin-immunoreactive neurons and their projections in the CNS. In: Björklund A, Hökfelt T, Kuhar MJ (eds) Handbook of chemical neuroanatomy, vol 3, Classical transmitters and transmitter receptors in the CNS, part II. Elsevier, Amsterdam, pp 68–125Google Scholar
  253. Steinbusch HW, Nieuwenhuys R, Verhoftad AA, Van der Kooy D (1981) The nucleus raphe dorsalis of the rat and its projections upon the caudo-putamen. A combined cytoarchitectonic, immunocytochemical and retrograde transport study. J Physiol Paris 77:157–174PubMedGoogle Scholar
  254. Steward LJ, Bufton KE, Hopkins PC, Davies WE, Barnes NM (1993) Reduced levels of 5-HT3 receptor recognition sites in the putamen of patients with Huntington’s disease. Eur J Pharmacol 242:137–143PubMedGoogle Scholar
  255. Steward LJ, Ge J, Stowe RL, Brown DC, Bufton RK, Stokes PRA, Barnes NM (1996) Ability of 5-HT4 receptor ligands to modulate rat striatal dopamine release in vitro or in vivo. Br J Pharmacol 117:55–62PubMedGoogle Scholar
  256. Suchowski CS, Galloway MP (1995) Serotonin receptor subtypes involved in the 5-HT facilitation of dopamine release in the striatum: microdialysis study in vivo. 25th Annual Meeting Society for Neurosciences, San Diego, California, abstract #152.9Google Scholar
  257. Sulzer D, Chen TK, Lau YY, Kristensen H, Rayport S, Ewing A (1995) Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport. J Neurosci 15:4102–4108PubMedGoogle Scholar
  258. Svenningsson P, Tzavara ET, Liu F, Fienberg AA, Nomikos GG, Greengard P (2002) DARPP-32 mediates serotonergic neurotransmission in the forebrain. Proc Natl Acad Sci USA 99:3188–3193PubMedGoogle Scholar
  259. Takaki M, Mawe GM, Barasch JM, Gershon MD, Gershon MD (1985) Physiological responses of guinea-pig myenteric neurons secondary to the release of endogenous serotonin by tryptamine. Neuroscience 16:223–240PubMedGoogle Scholar
  260. Tao R, Auerbach SB (1994) Increased extracellular serotonin in rat brain after systemic or intraraphe administration of morphine. J Neurochem 63:517–524PubMedGoogle Scholar
  261. Tao R, Auerbach SB (1995) Involvement of the dorsal raphe but not median raphe nucleus in morphine-induced increases in serotonin release in the rat forebrain. Neuroscience 68:553–561PubMedGoogle Scholar
  262. Tecott LH, Maricq AV, Julius D (1993) Nervous system distribution of the serotonin 3 receptor RNAm. Proc Natl Acad Sci USA 90:1430–1434PubMedGoogle Scholar
  263. Ternaux JP, Héry F, Bourgoin J, Adrien J, Glowinski J, Hamon M (1977) The topographical distribution of serotonergic terminals in the neostriatum of the rat and the caudate nucleus of the cat. Brain Res 121:311–326PubMedGoogle Scholar
  264. Thomas DR (2006) 5-HT5A receptors as a therapeutic target. Pharmacol Ther 111:707–714PubMedGoogle Scholar
  265. Thomas DR, Nelson DR, Johnson AM (1987) Biochemical effects of the antidepressant paroxetine, a specific 5-hydroxytryptamine uptake inhibitor. Psychopharmacology 93:193–200PubMedGoogle Scholar
  266. Thorré K, Ebinger G, Michotte Y (1998) 5-HT4 receptor involvement in the serotonin-enhanced dopamine efflux from the substantia nigra of the freely moving rat: a microdialysis study. Brain Res 796:117–124PubMedGoogle Scholar
  267. To ZP, Bonhaus DW, Eglen RM, Jakeman JB (1995) Characterization and distribution of putative 5-HT7 receptors in guinea pig brain. Br J Pharmacol 115:107–116PubMedGoogle Scholar
  268. Umbriaco D, Garcia S, Beaulieu C, Descarries L (1995) Relational features of acetylcholine, noradrenaline, serotonin and GABA axon terminals in the stratum radiatum of adult rat hippocampus (CA1). Hippocampus 5:605–620PubMedGoogle Scholar
  269. Van Bockstaele EJ, Pickel VM (1993) Ultrastructural of serotonin-immunoreactive terminals in the core and shell of the rat nucleus accumbens: cellular substrates for interactions with catecholamine afferents. J Comp Neurol 334:603–617PubMedGoogle Scholar
  270. Varnas K, Hall H, Bonaventure P, Sedvall G (2001) Autoradiographic mapping of 5-HT1B and 5-HT1D receptors in the post mortem human brain using [3H]GR 125743. Brain Res 915:47–57PubMedGoogle Scholar
  271. Varnas K, Thomas DR, Tupala E, Tiihonen J, Hall H (2004) Distribution of 5-HT7 receptors in the human brain: a preliminary autoradiographic study using [3H]SB-269970. Neurosci Lett 367:313–316PubMedGoogle Scholar
  272. Varnas K, Hurd YL, Hall H (2005) Regional expression of 5-HT1B receptor mRNA in the human brain. Synapse 56:21–28PubMedGoogle Scholar
  273. Vergé D, Daval G, Marcinkiewicz M, Patey A, El Mestikawy S, Gozlan H, Hamon M (1986) Quantitative autoradiography of multiple 5-HT1 receptors subtypes in the brain of control and 5,7-DHT treated rats. J Neurosci 6:3474–3482PubMedGoogle Scholar
  274. Vilaró MT, Cortes R, Gerald C, Branchek TA, Palacios JM, Mengod G (1996) Localization of 5-HT4 receptor mRNA in rat brain by in situ hybridization histochemistry. Mol Brain Res 43:356–360PubMedGoogle Scholar
  275. Vilaro MT, Cortes R, Mengod G (2005) Serotonin 5-HT4 receptors and their mRNAs in rat and guinea pig brain: distribution and effects of neurotoxic lesions. J Comp Neurol 484:418–439PubMedGoogle Scholar
  276. Waeber C, Palacios JM (1989) Serotonin-1 receptor binding sites in the human basal ganglia are decreased in Huntington’s chorea but not in Parkinson’s disease: a quantitative in vitro autoradiography study. Neuroscience 32:337–347PubMedGoogle Scholar
  277. Waeber C, Palacios JM (1994) Binding sites for 5-hydroxytryptamine-2 receptor agonists are predominantly located in striosomes in the human basal ganglia. Mol Brain Res 24:199–209PubMedGoogle Scholar
  278. Waeber C, Moskowitz MA (1995) [3H]sumatriptan labels both 5-HT1D and 5-HT1F receptor binding sites in the guinea pig brain: an autoradiographic study. Naunyn-Schmiedeberg’s Arch Pharmacol 352:263–275Google Scholar
  279. Waeber C, Sebben M, Nieoullon A, Bockaert J, Dumuis A (1994) Regional distribution and ontogeny of 5-HT4 binding sites in rodent brain. Neuropharmacology 33:527–541PubMedGoogle Scholar
  280. Waldmeier PC, Delini-Stula AA (1979) Serotonin–dopamine interactions in the nigrostriatal system. Eur J Pharmacol 55:363–373PubMedGoogle Scholar
  281. Ward RP, Dorsa DM (1996) Colocalization of serotonin receptor subtypes 5-HT2A, 5-HT2C and 5-HT6 with neuropeptides in rat striatum. J Comp Neurol 370:405–414PubMedGoogle Scholar
  282. Ward RP, Dorsa DM (1999) Molecular and behavioral effects mediated by Gs-coupled adenosine A2a, but not serotonin 5-HT4 or 5-HT6 receptors following antipsychotic administration. Neuroscience 89:927–938PubMedGoogle Scholar
  283. Ward RP, Hamblin MW, Lachowitcz JE, Hoffman BJ, Sibley DR, Dorsa DM (1995) Localization of serotonin subtype 6 receptor messenger RNA in the rat brain by in situ hybridization histochemistry. Neuroscience 64:1105–1111PubMedGoogle Scholar
  284. Wesolowska A (2002) In the search for selective ligands of 5-HT5, 5-HT6 and 5-HT7 serotonin receptors. Pol J Pharmacol 54:327–341PubMedGoogle Scholar
  285. West AR, Galloway MP (1996) Desensitization of 5-hydroxytryptamine-facilitated dopamine release in vivo. Eur J Pharmacol 298:241–245PubMedGoogle Scholar
  286. Westerink BHC, Tuntler J, Damsma G, Rollema H, De Vries JB (1987) The use of tetrodotoxin for the characterization of drug-enhanced dopamine release in conscious rats studied by brain microdialysis. Naunyn-Schmiedeberg’s Arch Pharmacol 336:502–507Google Scholar
  287. Westerink BH, Hofsteede HM, Tuntler J, de Vries JB (1989) Use of calcium antagonism for the characterization of drug-evoked dopamine release from the brain of conscious rats determined by microdialysis. J Neurochem 52:722–729PubMedGoogle Scholar
  288. Westfall C, Tittermary V (1982) Inhibition of the electrically induced release of [3H]dopamine by serotonin from superfused rat striatal slices. Neurosci Lett 28:205–209PubMedGoogle Scholar
  289. Westlund KN, Denney RM, Rose RM, Abell CW (1988) Localization of distinct monoamine oxidase A and monoamine oxidase B cell populations in human brainstem. Neuroscience 25:439–456PubMedGoogle Scholar
  290. Whitaker-Azmitia PM, Clarke C, Azmitia EC (1993) Localization of 5-HT1A receptors to astroglial cells in adult rats: implications for neuronal–glial interactions and psychoactive drug mechanism of action. Synapse 14:201–205PubMedGoogle Scholar
  291. Williams J, Davies JA (1983) The involvement of 5-hydroxytryptamine in the release of dendritic dopamine from slices of rat substantia nigra. J Pharm Pharmacol 35:734–737PubMedGoogle Scholar
  292. Willins DL, Meltzer HY (1998) Serotonin 5-HT2C agonists selectively inhibit morphine-induced dopamine efflux in the nucleus accumbens. Brain Res 781:291–299PubMedGoogle Scholar
  293. Wilkinson A, Courtney M, Westlind-Danielsson A, Hallnemo G, Akerman KE (1994) Alaproclate acts as a potent, reversible and noncompetitive antagonist of the NMDA receptor coupled ion flow. J Pharmacol Exp Ther 271:1314–1319PubMedGoogle Scholar
  294. White NM (1997) Mnemonic functions of the basal ganglia. Curr Opin Neurobiol 7:164–169PubMedGoogle Scholar
  295. Yadid G, Karel P, Kopin IJ, Goldstein DS (1994) Endogenous serotonin stimulates striatal dopamine release in conscious rats. J Pharmacol Exp Ther 270:1158–1165PubMedGoogle Scholar
  296. Yamamoto BK, Nash JF, Gudelsky GA (1995) Modulation of methylenedioxymethamphetamine-induced striatal dopamine release by the interaction between serotonin and gamma-aminobutyric acid in the substantia nigra. J Pharmacol Exp Ther 273:1063–1070PubMedGoogle Scholar
  297. Yeghiayan SK, Kelley AE (1995) Serotonergic stimulation of the ventrolateral striatum induces orofacial stereotypy. Pharmacol Biochem Behav 52:493–501PubMedGoogle Scholar
  298. Yeghiayan SK, Kelley AE, Kula NS, Campbell A, Baldessarini RJ (1997) Role of dopamine in behavioral effects of serotonin microinjected into rat striatum. Pharmacol Biochem Behav 56:251–259PubMedGoogle Scholar
  299. Yi SJ, Gifford AN, Johnson KM (1991) Effect of cocaine and 5-HT3 receptor antagonists on 5-HT induce [3H] dopamine release from rat striatal synaptosomes. Eur J Pharmacol 199:185–189PubMedGoogle Scholar
  300. Youdim MB, Feldman SC, Pappas GD, Pollard HB (1986) Serotonin metabolism and the nature of monoamine oxidase in squid central nervous system. Brain Res 381:300–304PubMedGoogle Scholar
  301. Zangen A, Nakash R, Overstreet DH, Yadid G (2001) Association between depressive behavior and absence of serotonin–dopamine interaction in the nucleus accumbens. Psychopharmacology (Berl) 155:434–439Google Scholar
  302. Zazpe A, Artaiz I, Del Rio J (1994) Role of 5-HT3 receptors in basal K+-evoked dopamine release from rat olfactory tubercule and striatal slices. Br J Pharmacol 113:968–972PubMedGoogle Scholar
  303. Zifa E, Fillion G (1992) 5-Hydroxytryptamine receptors. Pharmacol Rev 44:401–458PubMedGoogle Scholar
  304. Zhou FC, Lesch KP, Murphy DL (2002) Serotonin uptake into dopamine neurons via dopamine transporters: a compensatory alternative. Brain Res 942:109–119PubMedGoogle Scholar
  305. Zhou FM, Liang Y, Salas R, Zhang L, De Biasi M, Dani JA (2005) Corelease of dopamine and serotonin from striatal dopamine terminals. Neuron 46:65–74PubMedGoogle Scholar
  306. Zoldan J, Friedberg G, Livneh M, Melamed E (1995) Psychosis in advanced Parkinson’s disease: treatment with ondansetron, a 5-HT3 receptor antagonist. Neurology 45:1305–1308PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  1. 1.Unité Mixte de Recherche Centre National de la Recherche Scientifique 5227Université Victor Segalen Bordeaux 2BordeauxFrance

Personalised recommendations